Sign up to get updates from us
Medigene CEO, Dolores Schendel, takes us from her Midwestern roots to the helm of Bavaria’s Medigene AG. Along the way, she explains how her training at the hands of immunotherapy pioneers led to her recent move to deploy a novel molecular switch which protects and energizes Medigene’s TCR-T cells in their attack on solid tumors. (Plus, hear her talk about winning the prestigious Bavarian Order of Merit! For what, you ask? Well – give a listen…)
